CA2346264A1 - Glypicanes servant a detecter et a traiter le carcinome humain - Google Patents

Glypicanes servant a detecter et a traiter le carcinome humain Download PDF

Info

Publication number
CA2346264A1
CA2346264A1 CA002346264A CA2346264A CA2346264A1 CA 2346264 A1 CA2346264 A1 CA 2346264A1 CA 002346264 A CA002346264 A CA 002346264A CA 2346264 A CA2346264 A CA 2346264A CA 2346264 A1 CA2346264 A1 CA 2346264A1
Authority
CA
Canada
Prior art keywords
glypican
cells
growth factor
binding
egf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002346264A
Other languages
English (en)
Inventor
Arthur Lander
Murray Korc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2346264A1 publication Critical patent/CA2346264A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011—Phosphoinositide phospholipase C (3.1.4.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)

Abstract

Glypicane-1 HSPG ancré à glycosylphosphatidylinositol- (GPI-) est fortement exprimé dans le cancer du sein et du pancréas chez l'humain à la fois par les cellules cancéreuses et par les fibroblastes contigus dans le cas du cancer du pancréas, alors que l'expression de glypicane-1 est basse dans le pancréas normal et dans la pancréatite chronique. Le traitement de deux lignées cellulaires du cancer du pancréas, exprimant glypicane-1, par l'enzyme phospholipase-C spécifique pour phosphoinositide (PI-PLC) a supprimé leurs réactions mitogéniques à deux facteurs de croissance se fixant à héparine: le facteur-2 de croissance des fibroblastes (FGF2) et le facteur de croissance semblable à EGF se fixant à héparine (HB-EGF). Le traitement des cellules du cancer du sein MDA-MB-231 et MDA-MB-468 par PI-PLC a supprimé la réaction mitogénique à deux facteurs de croissance se fixant à héparine, le facteur de croissance semblable au facteur de croissance épidermique se fixant à héparine (HB-EGF) et le facteur-2 de croissance des fibroblastes (FGF-2). Syndecane-1 est également exprimé à des niveaux importants dans des tissus du cancer du sein, ainsi que dans des cellules du cancer du sein, par rapport à des tissus normaux du sein. La transfection temporaire ou permanente d'un produit génétique antisens de glypicane-1 a atténué les niveaux de protéines de glypicane-1 et la réaction mitogénique à FGF2 et HB-EGF. On peut utiliser glypicane afin de détecter le carcinome in vitro et des substances thérapeutiques qui soit se fixent (par exemple, anticorps ou médicaments) à la surface du domaine extracellulaire de glypicane-1, soit en suppriment (par exemple, enzymes) ou en empêchent l'expression (par exemple, produits génétiques antisens), sont efficaces pour retarder la croissance de carcinomes réactifs à glypicane.
CA002346264A 1998-10-16 1999-10-15 Glypicanes servant a detecter et a traiter le carcinome humain Abandoned CA2346264A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10451098P 1998-10-16 1998-10-16
US60/104,510 1998-10-16
US12162499P 1999-02-25 1999-02-25
US60/121,624 1999-02-25
PCT/US1999/024176 WO2000023109A1 (fr) 1998-10-16 1999-10-15 Glypicanes servant a detecter et a traiter le carcinome humain

Publications (1)

Publication Number Publication Date
CA2346264A1 true CA2346264A1 (fr) 2000-04-27

Family

ID=26801634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002346264A Abandoned CA2346264A1 (fr) 1998-10-16 1999-10-15 Glypicanes servant a detecter et a traiter le carcinome humain

Country Status (4)

Country Link
EP (1) EP1146903A4 (fr)
AU (1) AU769125B2 (fr)
CA (1) CA2346264A1 (fr)
WO (1) WO2000023109A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1412477A4 (fr) * 2001-07-12 2005-12-14 Exelixis Inc Glypicanes (gpc) utiles en tant que modificateurs des mecanismes de irrtk et de p21, methodes d'utilisation correspondantes
WO2004022597A1 (fr) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Anticorps d'un peptide n-terminal du gpc3 solubilise dans le sang
ATE425461T1 (de) * 2002-05-23 2009-03-15 Sunnybrook & Womens College Diagnose von hepatozellulärem karzinom
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
ES2805085T3 (es) * 2015-01-16 2021-02-10 Glyp Holdings Pty Ltd Epítopos de glipicano y usos de éstos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2116331T3 (es) * 1991-01-15 1998-07-16 Biotie Therapies Oy Deteccion del contenido en sindecan en los materiales biologicos tales como tejidos o fluidos fisiologicos que indican transformaciones celulares malignas.

Also Published As

Publication number Publication date
WO2000023109A1 (fr) 2000-04-27
AU769125B2 (en) 2004-01-15
EP1146903A4 (fr) 2005-02-16
AU1118100A (en) 2000-05-08
EP1146903A1 (fr) 2001-10-24

Similar Documents

Publication Publication Date Title
Kleeff et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer.
US20070026471A1 (en) Glypican-1 in human breast cancer
Matsuda et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells
Huang et al. Decreased Egr‐1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation
Berger et al. Evidence for a role of FGF‐2 and FGF receptors in the proliferation of non‐small cell lung cancer cells
US9987326B2 (en) Klotho protein and related compounds for the treatment and diagnosis of cancer
Rajkumar et al. The type I growth factor receptors in human breast cancer
Bernabeu et al. The emerging role of TGF-β superfamily coreceptors in cancer
Emami et al. Induction of scattering and cellular invasion by trefoil peptides in src‐and RhoA‐transformed kidney and colonic epithelial cells
US8354228B2 (en) Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy
Zhang et al. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice
Alper et al. Anti–sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell–adhesion and tumorigenicity in ovarian cancer cells
Hijazi et al. Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.
Fujimoto et al. Transforming growth factor-β1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells
Berasain et al. Amphiregulin: a new growth factor in hepatocarcinogenesis
Kleeff et al. Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells
Salomon et al. The role of amphiregulin in breast cancer
Xia et al. The expression, functions, interactions and prognostic values of PTPRZ1: a review and bioinformatic analysis
Colladel et al. MULTIMERIN2 binds VEGF-A primarily via the carbohydrate chains exerting an angiostatic function and impairing tumor growth
KR20060070491A (ko) 항종양 요법에 대한 종양 세포의 감수성 회복 및 세포 사멸유도를 위한 조성물 및 방법
Tseng et al. Inhibition of PAI-1 blocks PD-L1 endocytosis and improves the response of melanoma cells to immune checkpoint blockade
Murai et al. Overexpression of c-met in oral SCC promotes hepatocyte growth factor-induced disruption of cadherin junctions and invasion
Kornmann et al. IIIc isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells
US10555963B2 (en) Klotho protein and related compounds for the treatment and diagnosis of cancer
AU769125B2 (en) Glypicans for the detection and treatment of human carcinoma

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead